Table 1.
Drugs and inhibitors used in this screen.
| Inhibitor | Target proteins | Clinical use |
|---|---|---|
| AS-605240 | PI3Kγ | 3 |
| Axitinib | VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit | 1 |
| A66 | PI3K p110α | 3 |
| Bevacizumab | VEGF-A | 1 |
| BEZ-235 | PI3K p110γ/β/δ, mTOR | 3 |
| Cabozantinib | VEGFR2, c-Met, Ret, Klt, Flt1/3/4, Tle2, AXL | 2 |
| CAL-101 | PI3K p110δ | 2 |
| Cediranib | VEGFR, c-Kit, PDGFRβ, CSF-1R, Flt3 | 2 |
| Cisplatin | DNA-Synthesis | 1 |
| Crizotinib | cMET, ALK | 1 |
| Cyclopamine | smo (Smothened)-antagonist | 2 |
| Cyclophosphamide | alkylating agent | 1 |
| Dinaciclib | CDK1, CDK2, CDK5, CDK9 | 2 |
| Etopophos | Topoisomerase II Inhibitor | 1 |
| Everolismus | mTOR | 1 |
| Gemcitabine | DNA-analogue | 1 |
| GSK-J1 | H3K7 Histon-Demethylase | 2 |
| GDC-0941 | PI3Kα/δ | 2 |
| Pazopanib | VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit, c-Fms | 1 |
| Pemetrexed | Antifolat for TS, DHFR and GARFT | 1 |
| PI-103 | PI3K p110 α/β/γ/δ | 3 |
| Quirzatinib | Flt3, KIT, PDGFRα, PDGFRβ, RET, CSF-1R | 3 |
| TGX-221 | PI3K p110β | 3 |
| 3-Methyl-adenine | Vps34, PI3Kγ | 3 |
1 = clinically approved, 2 = clinical trial 3 = preclinical testing.